Autoimmune hepatitis as an adverse effect of long-term methotrexate therapy | Zendy

Kamilia Ksouda | Zendy; Hanen Affes | Zendy; Rim Atheymen | Zendy; M. Ezzeddine | Zendy; Khaled Zeghal | Zendy; Serria Hammami | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Autoimmune hepatitis as an adverse effect of long-term methotrexate therapy

Author(s) -

Kamilia Ksouda,

Hanen Affes,

Rim Atheymen,

M. Ezzeddine,

Khaled Zeghal,

Serria Hammami

Publication year - 2014

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.144940

Subject(s) - medicine , psoriasis , methotrexate , rheumatoid arthritis , psoriatic arthritis , autoimmune hepatitis , adverse effect , hepatitis , cirrhosis , arthritis , steatosis , immunology , drug , autoimmunity , dermatology , pharmacology , antibody

Methotrexate (MTX) is one of the most commonly used medicines in the treatment of psoriatic arthritis. The drug can produce steatosis and cirrhosis. Autoimmune hepatitis is a rare and serious adverse effect. We describe the case of a 53-year-old woman who developed autoimmune hepatitis after a long-term use of MTX for psoriatic arthritis. Hepatitis was completely resolved 4 months after stopping this drug. The pathophysiologic mechanisms of a drug-induced autoimmunity are unclear and complex. This report confirms the need to monitor liver enzymes carefully in patients using long-term treatment with MTX for psoriasis or rheumatoid arthritis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research